Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific
Portfolio Pulse from Lara Goldstein
Wesana Health Holdings (OTCQB:WSNAF) shareholders approved the sale of its SANA-013 development-related assets and other related assets to Lucy Scientific Discovery (NASDAQ:LSDI) and Lucy Scientific Discovery USA Inc. SANA-013 is a proprietary drug delivery protocol using a combination of psilocybin and CBD for the treatment of Major Depressive Disorder.
June 12, 2023 | 10:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wesana Health shareholders approved the sale of SANA-013 assets to Lucy Scientific Discovery, potentially impacting the company's stock price.
The approval of the asset sale could have a neutral impact on Wesana Health's stock price, as it may be seen as a positive development for the company's business strategy, but also as a loss of potential future revenue from the SANA-013 project.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Lucy Scientific Discovery will acquire SANA-013 assets from Wesana Health, potentially impacting the company's stock price.
The acquisition of SANA-013 assets could have a positive impact on Lucy Scientific Discovery's stock price, as it expands the company's portfolio and strengthens its position in the psychedelics market for treating Major Depressive Disorder.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100